Abstract
Sir, Anagrelide is an oral imidazo-quinazoline compound initially approved as a platelet-lowering agent in essential thrombocytosis (ET) by the Food and Drug Administration in 1997 [1]. It reduces platelet production, and at higher doses inhibits platelet aggregation, making it an ideal drug for use in ET [2, 3]. Furthermore, the shortand mediumterm benefits and side effects of anagrelide are now well established [4]. Although the drug is well tolerated by patients, experience with this drug during pregnancy in humans is limited [4–6]. Moreover, use of anagrelide in ET needs to be reviewed and one needs to be more cautious as it can lead to significant cardiotoxicity [7] and thrombotic complications [8]. Here we report the successful outcome of two patients with ET (Polycythemia Vera Study Group criteria) who inadvertently became pregnant while on anagrelide.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
